

Alicante, 11th November 2022

COMMUNICATION – MARKET NOTICE – FACEPHI BIOMETRIA, S.A.

Dear Sirs,

Pursuant to Article 17 of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (Market Abuse Regulation), and section 4.2.1 of Euronext Growth Markets Rule Book Part I: Harmonized Rules, on ongoing obligations of companies listed on Euronext, (hereinafter "FacePhi" or "the Company") hereby notifies the following:

On November the 10th 2022, under the delegation provided by the Extraordinary General Shareholders' Meeting of the Company held on January 2021, the Board of Directors granted a public deed about the resolution adopted by the Board on November the 7th 2022, about to produce a fourth issuance of 48,076,923 equity warrants convertible into Company' shares for a maximum conversion amount of 2,500,000 euros, the "Equity Warrants NOVEMBER 2022", with Nice & Green being the sole recipient of the issue of the Equity Warrants (NOVEMBER 2022).

Likewise, at the aforementioned General Meeting of January 25, 2021, specifically as set forth in section H - Delegation of Powers, it was agreed to delegate to the board of directors the power to modify, when deemed appropriate, the exercise conditions thereof and their respective term, as well as complete, clarify or modify the other terms and conditions of the Equity Warrants.

Therefore, under that said delegation, in use of the faculties of modification, the Board of Directors has considered as appropriate, to extend the exercise period for the conversion of the Warrants by the recipient, from 64 business days to 365 calendar days.

We remain at your disposal for any clarification you might deem necessary.

Sincerely,

Javier Mira Miró
Chairman of the Board of Directors